Literature DB >> 16816785

Suicide in bipolar disorder: Risks and management.

Ross J Baldessarini1, Maurizio Pompili, Leonardo Tondo.   

Abstract

Bipolar disorders are prevalent, often severe, and disabling illnesses with elevated lethality largely due to suicide. Suicide rates average approximately 1% annually, or perhaps 60 times higher than the international population rate of 0.015% annually. Suicidal acts typically occur early in bipolar disorders and in association with severe depressive or mixed states. The high lethality of suicidal acts in bipolar disorders is suggested by a much lower ratio of attempts:suicide (approximately 3:1) than in the general population (approximately 30:1). Risk factors can help to identify patients at increased suicidal risk, but ongoing clinical assessment is essential to limit risk. Empirical short-term interventions to manage acute suicidal risk include close clinical supervision, rapid hospitalization, and electroconvulsive therapy. Remarkably, however, evidence of the long-term effectiveness of most treatments against suicidal behavior is rare. A notable exception is lithium prophylaxis, which is associated with consistent evidence of major (approximately 80%), sustained relative reductions of risk of suicides and attempts, and lower lethality (increased attempts:suicide ratio). Such benefits are unproved for other treatments commonly used to treat bipolar disorder patients, including anticonvulsants, antipsychotics, antidepressants, and psychosocial interventions. Applying available knowledge systematically, with close and sustained clinical supervision, can enhance management of suicidal risk in bipolar disorders patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816785     DOI: 10.1017/s1092852900014681

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  43 in total

1.  Efficacy and Safety of Once- versus Twice-Daily Carbamazepine Extended-Release Capsules for the Treatment of Manic Symptoms in Patients with Bipolar I Disorder.

Authors:  Richard H Weisler; Amir H Kalali; Andrew J Cutler; Thomas D Gazda; Lawrence Ginsberg
Journal:  Psychiatry (Edgmont)       Date:  2008-03

Review 2.  Targeting renal purinergic signalling for the treatment of lithium-induced nephrogenic diabetes insipidus.

Authors:  B K Kishore; N G Carlson; C M Ecelbarger; D E Kohan; C E Müller; R D Nelson; J Peti-Peterdi; Y Zhang
Journal:  Acta Physiol (Oxf)       Date:  2015-05-04       Impact factor: 6.311

Review 3.  The increasing frequency of mania and bipolar disorder: causes and potential negative impacts.

Authors:  Sean H Yutzy; Chad R Woofter; Christopher C Abbott; Imad M Melhem; Brooke S Parish
Journal:  J Nerv Ment Dis       Date:  2012-05       Impact factor: 2.254

4.  Cyclothymic disorder in youth: why is it overlooked, what do we know and where is the field headed?

Authors:  Anna R Van Meter; Eric A Youngstrom
Journal:  Neuropsychiatry (London)       Date:  2012-12-01

Review 5.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

6.  Working With a Patient With Bipolar I Disorder Who Is Experiencing Depression.

Authors:  Jeffrey J Rakofsky
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-07-16

7.  Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder.

Authors:  Robert D Gibbons; Kwan Hur; C Hendricks Brown; J John Mann
Journal:  Arch Gen Psychiatry       Date:  2009-12

8.  Does Attention Deficit Hyperactivity Disorder increase the risk of suicide attempts?

Authors:  Vito Agosti; Ying Chen; Frances R Levin
Journal:  J Affect Disord       Date:  2011-06-11       Impact factor: 4.839

9.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

10.  Clozapine for Treatment-Refractory Aggressive Behavior.

Authors:  Teodorescu Andreea; Ifteni Petru; Ana Aliana Miron; Petric Paula-Simina; Dima Lorena
Journal:  Psychiatr Q       Date:  2020-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.